LUPIN LIMITED

Lupin re-launches Humrahi at RSSDI conference, now offering comprehensive support for diabetes and heart health. Humrahi aims to improve patient outcomes through value-based care and education, accessible via app or toll-free number.

The Global Pharma 4.0 Market is projected to grow from US$ 11.9 Billion in 2023 to US$ 67.7 Billion by 2033, driven by digital transformation strategies, AI, IoT, and blockchain. Key segments include AI & ML leading technology with 33.4% share, drug discovery & development with 37.8%, and pharmaceutical companies as the dominant end-user with 42.6%. North America leads with 39.7% market share, while Asia Pacific is expected to grow fastest.

Lupin receives tentative U.S. FDA approval for Raltegravir tablets, potentially securing 180-day exclusivity for a generic version of Merck’s Isentress HD. The drug, manufactured at Lupin’s Nagpur facility, treats HIV-1 infection and is expected to impact the $36 million U.S. market.

Lupin's leadership anticipates strong double-digit growth in FY25, with India's robust market and diabetes segment recovery. The US business focuses on new product launches and sustained profitability, targeting a core margin of 23-25%.

Lupin receives tentative USFDA approval for Raltegravir Tablets, 600 mg, a generic equivalent of Merck's Isentress HD, to be manufactured at its Nagpur facility. The drug treats HIV-1 in adults and pediatric patients weighing at least 40 kg, with estimated U.S. sales of $36 million.

Lupin Limited received tentative FDA approval for its generic raltegravir tablets USP, 600 mg, equivalent to Merck's Isentress HD. Lupin is the exclusive first-to-file and may receive 180-day exclusivity. The product treats HIV-1 in adults and pediatric patients weighing at least 40 kg, with an estimated annual US sales of USD 36 million.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

Lupin launches first generic of Pred Forte (Prednisolone Acetate Ophthalmic Suspension) in the US, receiving 180-day CGT exclusivity.

Lupin Limited launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the U.S., receiving 180-day competitive generic therapy exclusivity. The drug treats steroid-responsive inflammation and had estimated annual sales of USD 198 million.

Titan Company Q2: Total business +25%, jewellery +26%, watches & wearables +20%, EyeCare +6%, emerging businesses +14%, CaratLane +28%, 75 new stores. Induslnd Bank Q2: Net advances +13%, deposits +15%, CASA ratio 35.9%. Bandhan Bank Q2: Loans +21.4%, deposits +27.2%, CASA ratio 33.2%. Poonawalla Fincorp Q2: AUM +40%, liquidity Rs 5,700 crore. Jammu & Kashmir Bank Q2: Total business +9.2%, deposits +8.96%, gross advances +8.3%, CASA ratio 48.61%. AU Small Finance Bank Q2: Deposits +12.7%, gross advances +5.9%, CASA ratio 32.4%. IDBI Bank Q2: Total business +15%, deposits +11%, net advances +19%, CASA deposits +4%. RBL Bank Q2: Deposits +20%, advances +15%, CASA ratio 33.5%. Godrej Properties Q2: Booking value +3%, collections +68%, OCF +120%. L&T Finance Q2: Retailisation 96%, retail disbursements +12%, retail loan book +28%. Macrotech Developers Q2: Pre-sales +21%, collections +11%. Federal Bank Q2: Advances +19.3%, deposits +15.6%, CASA +11.5%, CASA ratio 30.07%. Metropolis Healthcare Q2: Revenue +13%, B2C revenue +20%, 6 labs and 120 centers added. Indian Bank Q2: Total business +9.8%, deposits +8.1%, gross advances +12%. Union Bank of India Q2: Global deposits +9.17%, global gross advances +9.63%, domestic CASA deposits +2.06%, domestic deposits +8.12%, domestic advances +8.88%. Utkarsh Small Finance Bank Q2: Gross loans +28.3%, deposits +39.6%, CASA deposits +37.1%, CASA ratio 19.6%. Equitas Small Finance Bank Q2: Deposits +29.3%, gross advances +15.4%, CASA +17.4%, CASA ratio 31%. Dhanlaxmi Bank Q2: Advances +6.9%, deposits +5.9%, CASA +7.97%, gold loan +29.9%. Ujjivan Small Finance Bank Q2: Deposits +17%, CASA +26%, CASA ratio 25.9%, gross loan book +14%, disbursements -7%. Adani Wilmar Q2: Edible oil volume +15%, food & FMCG volume +31%, industry essentials volume -16%. Stocks to watch: Jio Financial Services, GAIL (India), Lupin, Antony Waste Handling Cell, Univa Foods, BLS International Services, One 97 Communications (Paytm), Gravita India, Reliance Chemotex Industries, Mahanagar Telephone Nigam (MTNL), Bank of Maharashtra, CG Power & Industrial Solutions, RKEC Projects, Apollo Tyres, Akzo Nobel India, TVS Supply Chain Solutions, Landmark Cars, Adani Energy Solutions. Bulk deals: Diffusion Engineers, Zaggle Prepaid Ocean Services, R Systems International, Hawkins Cookers. Block deals: HDFC Bank. SME listing: HVAX Technologies, Saj Hotels. Stocks turn ex-dividend: Jupiter Wagons, KP Energy. Stocks trade ex-bonus: NBCC (India). Stock trades ex-date for rights: Geojit Financial Services. F&O ban: GNFC, Bandhan Bank, Birlasoft, Granules India, Hindustan Copper, Manappuram Finance, RBL Bank.